Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 47 for “"BRAF mutations"”.

  1. Genetics of cutaneous malignant melanoma

    … analysis of these families shows germline mutations of CDKN2A in 20-30% of patients. This thesis has investigated 48 Scottish families with cutaneous malignant melanoma and also 28 patients with sporadic melanoma for mutations in the CDKN2A, MCIR and BRAF genes using molecular genetic …

    glasgow Download PDF for Genetics of cutaneous malignant melanoma (opens in a new tab)

  2. New therapeutic concepts for BRAF-driven colorectal cancer

    The kinase-activating BRAFV600E mutation occurs in about 10 % of colorectal cancer (CRC) patients and confers a poor prognosis. In order to evaluate novel treatment approaches such as the combination of immunotherapy with kinase inhibition, syngeneic preclinical models are urgently needed, but …

    freiburg-diss Repository record for New therapeutic concepts for BRAF-driven colorectal cancer (opens in a new tab)

  3. Μελέτη της έκφρασης των γονιδίων EGFR, RAS που εμπλέκονται στο μονοπάτι μεταγωγής σήματος του υποδοχέα του επιδερμικού αυξητικού παράγοντα σε συμπαγείς όγκους

    … study we investigated the presence of KRAS / BRAF mutations and their correlation with the clinical-histopathological parameters in 322 patients with colon cancer. In addition, we collected fresh paired tumor and normal tissue from 50 patients and investigated the expression level of KRAS and …

    greece Repository record for Μελέτη της έκφρασης των γονιδίων EGFR, RAS που εμπλέκονται στο μονοπάτι μεταγωγής σήματος του υποδοχέα του επιδερμικού αυξητικού παράγοντα σε συμπαγείς όγκους (opens in a new tab)

  4. Potential Targeted Therapeutic Strategies for Overcoming Resistance in BRAF Wild Type Melanoma

    … 50% of all melanoma patients possess activating BRAF mutations ignited a significant paradigm shift in the way the melanoma field approached research and how patients were treated [1]. The era of targeted therapy had begun and with it came successful targeted BRAF inhibitor therapy regimens, …

    usf Repository record for Potential Targeted Therapeutic Strategies for Overcoming Resistance in BRAF Wild Type Melanoma (opens in a new tab)

  5. Identification of therapeutic targets in canine bladder cancer: a translational model for MAPK pathway-targeted and immune-based therapies

    Activating mutations in the proto-oncogene BRAF are drivers of oncogenesis in several human cancers, including melanoma, thyroid and colorectal carcinomas, and hairy-cell leukemia. Small molecule inhibitors targeting oncogenic BRAF demonstrate initial efficacy in approximately 50% of BRAF mutant …

    colostate Repository record for Identification of therapeutic targets in canine bladder cancer: a translational model for MAPK pathway-targeted and immune-based therapies (opens in a new tab)

  6. Protein kinase C δ is a potential therapeutic target in malignant melanoma with NRAS mutation or B-RAF inhibitor-resistance

    … the impressively high rates of response to BRAF inhibitors in patients with melanomas harboring BRAF mutations, most of these patients eventually relapse after developing resistance to the drug, due in part to secondary mutations in NRAS. Although NRAS mutation is the second most common …

    bu Repository record for Protein kinase C δ is a potential therapeutic target in malignant melanoma with NRAS mutation or B-RAF inhibitor-resistance (opens in a new tab)

  7. Expression of BRAF V600E mutation in osteoclasts: a murine model of bone erosion in histiocytosis-like disease

    BRAF is a serine/threonine protein kinase which regulates proliferation, differentiation, and apoptosis of cells as a downstream effector in the RAS-RAF-MEK-ERK/MAPK signaling pathway. Activating mutations in the BRAF gene can induce excessive cell growth and survival and are found in a wide range …

    bu Repository record for Expression of BRAF V600E mutation in osteoclasts: a murine model of bone erosion in histiocytosis-like disease (opens in a new tab)

  8. Morphologische Charakterisierung der BRAF mutierten Melanome mittels Immunhistochemie, Dermatoskopie und konfokaler Laserscanmikroskopie

    … can be distinguished based on the presence of BRAF mutations. Estimated 40-60% of melanomas harbour a BRAF mutation, most of them V600E. Current guidelines recommend testing every advanced melanoma for BRAF mutation, since BRAF inhibitors are available for both adjuvant and therapeutic setting. …

    lmu-germany Repository record for Morphologische Charakterisierung der BRAF mutierten Melanome mittels Immunhistochemie, Dermatoskopie und konfokaler Laserscanmikroskopie (opens in a new tab)

  9. Μοριακή και ανοστοϊστοχημική διερεύνηση της μικροδορυφορικής αστάθειας (MSI) σε καρκινώματα παχέος εντέρου

    … sequencing were applied to identify KRAS, BRAF, NRAS mutations and Microsatellite instability (MSI) status. Immunohistochemistry was used to characterize the associated Mismatch Repair Protein loss. Statistical calculations were performed using the statistical package SPSS v21.0. Results: …

    greece Repository record for Μοριακή και ανοστοϊστοχημική διερεύνηση της μικροδορυφορικής αστάθειας (MSI) σε καρκινώματα παχέος εντέρου (opens in a new tab)

  10. BRAF V600E mutacijos ir citomorfologinių požymių reikšmė papilinio skydliaukės vėžio diagnostikos optimizavimui /

    … disease course. The first works on the impact of BRAF mutations in oncological diseases were performed in studies of skin, colon and lung tumors. The link between BRAF mutations and PTC was confirmed in publications in 2003. A high V400E mutation specificity for PTC was noticed at that time. …

    vilnius Repository record for BRAF V600E mutacijos ir citomorfologinių požymių reikšmė papilinio skydliaukės vėžio diagnostikos optimizavimui / (opens in a new tab)

  11. The significance of the BRAF V600E mutation and the cytomorphological features for the optimization of papillary thyroid cancer diagnostics /

    … disease course. The first works on the impact of BRAF mutations in oncological diseases were performed in studies of skin, colon and lung tumors. The link between BRAF mutations and PTC was confirmed in publications in 2003. A high V400E mutation specificity for PTC was noticed at that time. …

    vilnius Repository record for The significance of the BRAF V600E mutation and the cytomorphological features for the optimization of papillary thyroid cancer diagnostics / (opens in a new tab)

  12. Μεταλλαγές και έκφραση των ογκογονιδίων RAS και BRAF στον καρκίνο της ουροδόχου κύστης

    … society. We determined RAS codon 12 and 13 point mutations and evaluated mRNA expression levels in transitional cell carcinoma cases. Mutational activation of the MAP kinase pathway is frequently found in many types of cancer. Recently, activating mutations in the BRAF gene, an important activator …

    greece Repository record for Μεταλλαγές και έκφραση των ογκογονιδίων RAS και BRAF στον καρκίνο της ουροδόχου κύστης (opens in a new tab)

  13. Targeted Oncogene Mutation Detection in Non-Small Cell Lung Cancer by Multiplexed Array Mass Spectrometry Genotyping: Results of a Clinical Validation Study

    … discovery of cancer driver genes and somatic mutations in lung cancer patient sub-groups has seen the emergence of genetic abnormalities being used in the treatment of lung cancer as predictive bio-markers and molecular targets for targeted cancer therapy especially in Non-small Cell Lung …

    auckland-tech Repository record for Targeted Oncogene Mutation Detection in Non-Small Cell Lung Cancer by Multiplexed Array Mass Spectrometry Genotyping: Results of a Clinical Validation Study (opens in a new tab)

  14. Proteomic and molecular analysis in colorectal cancer: validation of the biomarkers desmin, SET and CK8.

    … 73 and 431 residues and 50% of CRC patients have mutations in the EGFR/Ras/Raf/MEK/ERK signalling pathway (KRAS or BRAF mutations) resulting in constitutive ERK activation. Inhibition of EGFR activation in Caco2 cells showed a significant decrease (P<0.0001) in PS73 and PS431 levels by 59% and 65% …

    adelaide Repository record for Proteomic and molecular analysis in colorectal cancer: validation of the biomarkers desmin, SET and CK8. (opens in a new tab)

  15. Mismatch Repair Deficient Tumors Lacking Known Sporadic Causes: Are They All Due to Lynch Syndrome?

    … absence of MLH1 promoter hypermethylation and BRAF mutations are suggestive of Lynch syndrome (LS). Positive germline genetic test results confirm LS. It is unclear if individuals with MMRD tumors but no identified germline mutation or sporadic cause (MMRD+/germline-) have LS. HYPOTHESIS: Since …

    uthsc Repository record for Mismatch Repair Deficient Tumors Lacking Known Sporadic Causes: Are They All Due to Lynch Syndrome? (opens in a new tab)

Page 1 of 3